Company Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Caribou Biosciences, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:13:22 2024-06-05 pm EDT			5-day change	1st Jan Change
2.115 ^USD	-2.31%		-28.12%	-63.87%

Jun. 04	US Equities Markets Close Mixed Monday as US Manufacturing Contracts	MT
Jun. 04	HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating	MT

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Number of employees: 158

USD in Million	2022	Weight	2023	Weight	Delta
Allogeneic CAR-T and CAR-NK Cell Therapies 100.0 %	14	100.0 %	34	100.0 %	+148.91%

USD in Million	2022	Weight	2023	Weight	Delta
United States 95.0 %	13	96.0 %	33	95.0 %	+146.34%
Rest of World 5.0 %	1	4.0 %	2	5.0 %	+211.50%

Managers	Title	Age	Since
Rachel Haurwitz FOU	Founder	37	11-10-27
Jason O’Byrne DFI	Director of Finance/CFO	55	21-02-08
Steven Kanner CTO	Chief Tech/Sci/R&D Officer	65	17-05-31
Timothy Kelly CTO	Chief Tech/Sci/R&D Officer	55	Jan. 06
Reigin Zawadzki HRO	Human Resources Officer	-	23-09-26
Cindy Hayashi HRO	Human Resources Officer	-	16-07-31
Ryan Fischesser AUD	Comptroller/Controller/Auditor	-	-
Elaine Alambra LAW	General Counsel	-	-
Ruhi Khan PRN	Corporate Officer/Principal	49	21-11-07
Barbara McClung LAW	General Counsel	69	15-03-31

Members of the board	Title	Age	Since
Andrew Guggenhime CHM	Chairman	55	21-03-31
Scott Braunstein BRD	Director/Board Member	60	21-05-31
Dara Richardson-Heron BRD	Director/Board Member	60	21-11-07
Rachel Haurwitz FOU	Founder	37	11-10-27
Natalie Sacks BRD	Director/Board Member	59	18-04-30
David Johnson BRD	Director/Board Member	55	22-05-10
Ran Zheng BRD	Director/Board Member	61	21-09-23
Nancy Whiting BRD	Director/Board Member	51	21-08-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	90,317,771	81,234,137 ( 89.94 %)	0	89.94 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 7.290 %	6,583,782	7.290 %	25 M $
PFM Health Sciences LP 7.179 %	6,483,270	7.179 %	24 M $
STATE STREET CORPORATION 7.028 %	6,347,321	7.028 %	24 M $
Avidity Partners Management LP 6.406 %	5,785,352	6.406 %	22 M $
PFIZER, INC. 5.193 %	4,690,431	5.193 %	18 M $
Vanguard Fiduciary Trust Co. 4.552 %	4,110,795	4.552 %	15 M $
Point72 Asset Management LP 3.969 %	3,585,018	3.969 %	13 M $
Rachel Haurwitz 3.753 %	3,389,395	3.753 %	13 M $
Oppenheimer Asset Management (Alkeon Subfiler) 3.038 %	2,743,505	3.038 %	10 M $
Elmwood Wealth Management, Inc. 2.618 %	2,364,240	2.618 %	9 M $

Caribou Biosciences, Inc.

2929 7th Street Suite 105

94710, Berkeley

http://www.cariboubio.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.165 USD

Average target price

17.88 USD

Spread / Average Target

+725.64%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARIBOU BIOSCIENCES, INC.	-63.87%	196M
MODERNA, INC.	+53.93%	55.7B
LONZA GROUP AG	+41.08%	39.91B
IQVIA HOLDINGS INC.	-5.72%	39.57B
CELLTRION, INC.	-5.56%	28.16B
ICON PUBLIC LIMITED COMPANY	+16.41%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-20.14%	18.94B
MEDPACE HOLDINGS, INC.	+32.87%	12.17B
UNITED THERAPEUTICS CORPORATION	+26.88%	12.12B
BIO-TECHNE CORPORATION	+2.18%	12.12B

Other Biotechnology & Medical Research